Journal Of Clinical Oncology Publishes Results Of Corcept's Phase 2 Trial Of Relacorilant In Women With Platinum-Resistant Ovarian Cancer
Portfolio Pulse from Bill Haddad
The Journal of Clinical Oncology has published the results of Corcept Therapeutics' Phase 2 trial of Relacorilant in women with platinum-resistant ovarian cancer. The trial demonstrated promising results, potentially benefiting Corcept's stock (CORT).
June 27, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics' Phase 2 trial of Relacorilant showed promising results in treating platinum-resistant ovarian cancer, potentially boosting the company's stock.
The publication of positive results from Corcept's Phase 2 trial in the Journal of Clinical Oncology indicates that Relacorilant has potential as a treatment for platinum-resistant ovarian cancer. This news is likely to be seen as a positive development for the company and may lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100